I am a
Home I AM A Search Login

Papers of the Week

2021 Feb 17

J Acquir Immune Defic Syndr

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.


Kumar P, Johnson M, Molina J-M, Rizzardini G, Cahn P, Bickel M, Wan H, Xu Z J, Morais C, Sklar P, Greaves W
J Acquir Immune Defic Syndr. 2021 Feb 17.
PMID: 33633036.


In the primary analysis of the DRIVE-SHIFT trial, switching to doravirine/lamivudine/ tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression of HIV-1 through Week 48. Here we present long-term efficacy and safety outcomes through Week 144 of the DRIVE-SHIFT trial.